

Are you a Polycythemia Vera patient interested in participating in a research study?



A Phase 1/2 Study in Polycythemia Vera

ClinicalTrials.gov Identifier: **NCT05499013**



You may qualify for Phase 2:

a) If you previously completed Phase 1 of this study:

1. You must have completed Phase 1 study, 6 months before the start of Phase 2, and had 3 or more venesections (bloodletting sessions) in the 28 weeks before the start of Phase 2.
2. If you are taking cytoreductives; medications that help reduce the number of blood cells thereby preventing vascular events, you can participate if you are on a stable dose.

b) If you did not take part in Phase 1 of this study:

1. You are 18 years old or older.
2. Have been diagnosed with Polycythemia Vera.
3. Have had 3 or more venesections (bloodletting sessions in the last 28 weeks (7 months) or 5 or more times in the last 12 months.
4. Your hematocrit level is being monitored and controlled.
5. If you are taking cytoreductives: medications that help reduce the number of blood cells thereby preventing vascular events, you can participate if you are on a stable dose.

c) For all potential patients:

1. Do not have more than one significant disease or condition at the same time.
2. Sign consent and agree to participate in all study visits.

Note: there are additional criteria required which will be checked by the study doctor



Participation involves:

- A screening period to assess if you are eligible to participate in the study.
- Treatment for a duration of 180 weeks (over 3 years): 36 weeks (approximately 9 months) of treatment with the study drug or placebo (an inactive substance – saline) followed by treatment with the study drug for 144 weeks (approximately 3 years).



Potential benefits and side effects:

- Participating in this study may improve the management of your Polycythemia Vera.
- There is a risk that the study drug may not be as effective as the usual approach for treating your Polycythemia Vera.
- As with all medications, there are potential side effects associated with the study drug. One of the potential side effects you may experience is temporary pain in the injection site.



For more information:

Please complete the form on the Silence Therapeutics website: [Silence Therapeutics - Patients - Clinical Trials - A Platform for Progress: Our Clinical Studies - Indication Polycythemia Vera](#)